Gilead must conduct another study of cystic fibrosis drug, FDA says
This article was originally published in Scrip
Executive Summary
Gilead Scienceswill need to conduct another clinical trial of its investigational cystic fibrosis treatment aztreonam lysine for inhalation before the drug can be approved, the US FDAhas said.